Abstract: Angiogenesis, the process of generating new blood vessels, is essential to embryonic development, organ formation, tissue regeneration and remodeling, reproduction and wound healing. Also, it plays an important role in many pathological conditions, including chronic inflammation and cancer. Angiogenesis is regulated by a complex interplay of growth factors, inflammatory mediators, adhesion molecules, morphogens and guidance molecules. Transcription factor SOX18 is transiently expressed in nascent endothelial cells during embryonic development and postnatal angiogenesis, but little is known about signaling pathways controlling its expression. The aim of this study was to investigate whether pro-angiogenic molecules and pharmacological inhibitors of angiogenesis modulate SOX18 expression in endothelial cells. Therefore, we treated human umbilical vein endothelial cells (HUVEC) with angiogenic factors, extracellular matrix proteins, inflammatory cytokines and nonsteroidal anti-inflammatory drugs (NSAID) and monitored SOX18 expression. We have observed that the angiogenic factor VEGF and the inflammatory cytokine TNF increase, while the NSAID ibuprofen and NS398 decrease the SOX18 protein level. These results for the first time demonstrate that SOX18 expression is modulated by factors and drugs known to positively or negatively regulate angiogenesis. This opens the possibility of pharmacological manipulation of SOX18 gene expression in endothelial cells to stimulate or inhibit angiogenesis.
Introduction
Angiogenesis is an essential physiological process in which new blood vessels are generated from preexisting ones. It is essential to embryonic development, organ formation, tissue regeneration and remodeling, reproduction and wound healing [1] [2] [3] . Angiogenesis is regulated by a complex interplay of growth factors, adhesion molecules, morphogens and endogenous inhibitors, and the imbalance between these factors contributes to abnormal angiogenesis in numerous diseases [4] . Angiogenesis is also a critical event in the transition of tumors from a premalignant to a malignant state and from a dormant lesion to growing tumors [5, 6] . Thus, controlling angiogenesis, either positively or negatively, is considered to be a promising strategy for the treatment of various diseases. SOX proteins constitute a large family of diverse and well-conserved transcription factors implicated in the control of different developmental processes [7, 8] . The Sox18/SOX18 is the member of SOX gene family that is transiently expressed in nascent endothelial cells during embryonic development and adult neovascularization [9] . The functional importance of SOX18 protein in vascular development is demonstrated by vascular defects observed in mice and humans bearing Sox18/SOX18 mutations. For example, mutations in Sox18 underlie the phenotype of ragged mutant mouse characterized by abnormalities in its coat and cardiovascular system [10] . Furthermore, murine Sox18 is shown to be involved in the induction of angiogenesis during wound healing and tissue repair [11] . Also, it has been demonstrated that interfering with Sox18 function inhibits blood vessel formation and subsequent tumor growth [12] . In humans, SOX18 mutations are associated with hypotrichosislymphedema-telangiectasia syndrome [13] .
Numerous pro-angiogenic molecules have been identified including members of the vascular endothelial growth factor (VEGF) family, angiopoietins, transforming growth factors (TGF), platelet-derived growth factor (PDGF), tumor necrosis factor (TNF), interleukins and the members of the fibroblast growth factor (FGF) family [14] . Importantly, some of these molecules, especially growth factors and their receptors, have emerged as valuable therapeutic targets for anti-angiogenic strategies [15, 16] . Although diverse transcription factors control the angiogenic phenotype of endothelial cells and represent key regulators of normal and pathological angiogenesis, only limited number of transcription factors are recognized as mediators of pro-angiogenic signals to target genes [17, 18] . While SOX18 has been identified as one important transcription factor controlling blood vessel formation, little is known about extracellular cues and intracellular signaling pathways controlling its expression in endothelial cells.
Our past work has been focused on the characterization of the 5' regulatory region of the human SOX18 gene and the identification of transcription factors involved in regulation of its expression [19, 20] . We have characterized the promoter region of SOX18 and demonstrated that specificity protein 3 (Sp3), zinc finger binding protein 89 (ZBP-89) and nuclear factor Y (NF-Y) are involved in the regulation of SOX18 gene expression in the HeLa cell line [19, 20] . Furthermore, in a search for transcription factors involved in regulation of SOX18 gene expression that are also relevant for the control of angiogenesis, we have recently identified early growth response 1 (EGR1) as an activator of SOX18 promoter activity [21] .
The aim of this study was to investigate the effect of selected pro-angiogenic molecules and inhibitors of angiogenesis on SOX18 expression in human umbilical vein endothelial cells (HUVEC). The novel findings presented here would contribute to the unraveling involvement of SOX18 in signaling events relevant to angiogenesis.
Experimental Procedures

Cell culture
HUVEC were isolated from umbilical cords, as described earlier [22] , using protocols approved by the Ethic Committee of the Faculty of Biology and Medicine of the University of Lausanne. HUVEC were cultured in M199 basal medium (Invitrogen, Carlsbad, CA), supplemented with 12 μg/ml bovine brain extract (Clonetics, Walkersville, MA), 10 ng/ml human recombinant epidermal growth factor (Genzyme, Cambridge, MA), 25 units/ml heparin, and 1 μg/ml hydrocortisone (Sigma Aldrich, St Louis, MO). Sub-confluent cultures were treated for different periods of time with various growth factors, TNF and NSAID with final concentrations presented at Table 1 . For de novo cell attachment experiments, HUVEC were collected by treatment with trypsin (Invitrogen), resuspended in serum-free M199 medium, incubated for 2 hours at 37°C in suspension, and subsequently plated in 10 cm dish pre-coated with different ECM proteins ( Table 1) . After 3 hours, which is approximately the minimal period for full attachment of cells, cells were collected and total protein extracts were prepared, as described below.
RT-PCR
Total RNAs from HeLa and EA.hy926 cells were isolated using TRI-Reagent (Ambion, Austin, TX), while total RNA from HUVEC was isolated using RNAzol reagent (Tel-Test, Inc, Friendswood, TX) and 1 µg of each RNA was reverse transcribed using MuLV reverse transcriptase (Applied Biosystems, Foster City, CA) and random hexamers (Applied Biosystems). cDNAs were subjected to RT-PCR using Kapa Fast HS Ready Mix PCR Kit (Kapa Biosystems, Woburn, MA). SOX18 gene was amplified using the following primers: forward, 5′ TTCCATGTCACAGCCCCCTAG 3′, and reverse 5′ GACACGTGGGAACTCCAG 3′. GAPDH was amplified using the following primers: forward, 5′ GGACCTGACCTGCCGTCTAG 3′ and reverse, 5′ CCACCACCCTGTTGCTGTAG 3′. Products were separated on 2% agarose gel.
Western blot
Untreated and treated HUVEC were washed twice in cold PBS, and collected in RIPA buffer (25 mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) followed by centrifugation at 14,000 × g for 15 minutes to pellet the cell debris. Total protein extracts were separated by SDS-PAGE electrophoresis and analyzed by Western blotting using primary rabbit anti-SOX18 antibody (Santa Cruz Biotechnology, Santa Cruz, CA; sc-20100), mouse anti-actin monoclonal antibody (Sigma; A3853) and mouse anti-α-tubulin antibody (Calbiochem, Darmstadt, Germany, CP06). Immunoreactive bands were detected using HRP-conjugated anti-rabbit IgG or anti-mouse IgG and ECL detection kit (all obtained from Amersham Pharmacia Biotech, Sunnyvale, CA). Immunoblots were digitalized and quantified with ImageQuant Version 5.2 software (Amersham Pharmacia Biotech) and normalized for actin or α-tubulin values. The quantities of SOX18 protein were calculated as a percentage of control HUVEC, which was set as 100%. Data of at least two independent experiments are presented at histograms as the means ± SD. Mean values of relative SOX18 expression were compared with Student's t-test. Statistical analyses were performed using SPSS software. A P value of less than 0.05 was considered significant.
Results and Discussion
SOX18 gene is expressed in HUVEC
The human SOX18 gene is transiently expressed in nascent endothelial cells during embryonic development and postnatal angiogenesis. Therefore, we have started our study by analyzing SOX18 gene expression in primary endothelial cells by using HUVEC, a wellestablished endothelial model system. In addition to RNA isolated from HUVEC, we included in this analysis RNAs isolated from HeLa cells and EA.hy926 endothelial cells. Namely, we used RT-PCR method in order to analyze the expression of SOX18 gene in HUVEC, while HeLa and EA.hy926 cells served as positive controls, for which we have previously shown to express SOX18 [19, 21] . As presented at Figure 1 , after 12 cycles of amplification no products could be detected for either SOX18 or GAPDH gene. Then, after 24 cycles of amplification, SOX18 product starts to appear in HUVEC, while GAPDH is detectable in all tested cells at the similar level. After 35 cycles of amplification in all tested cells we detected the amplification of SOX18 gene product and without obvious changes in GAPDH level between analyzed samples. Results of this analysis demonstrated that HUVEC express SOX18 gene, and that the relative level of its expression is higher compared to HeLa or EA.hy926 cells. By this we have confirmed that these cells are an appropriate model system for further study.
The effect of pro-angiogenic growth factors on SOX18 protein level in HUVEC
Growth factors are naturally occurring proteins capable of stimulating variety of cellular processes, including cell growth, proliferation and differentiation. VEGF, bFGF (also known as FGF-2), and TGF-β play prominent and well-documented roles in angiogenesis [23, 24] . Importantly, VEGF expression correlates with tumor vascularity and progression in many cancers [25] . Inhibition of VEGF results in decreased tumor vascularity and growth, implicating VEGF as the major tumor angiogenesis factor. Anti-VEGF therapies are currently used in oncology to treat metastatic cancers [26] .
We have tested the effect of VEGF, bFGF and TGF-β on SOX18 protein level in HUVEC ( Table 1) . As presented on Figure 2A and B, treatments with bFGF for 1 h and 3 h and TGF-β for 3 h did not cause changes in the SOX18 protein level. Next, we have performed VEGF treatment of HUVEC for 0.5 h, 1 h, 3 h and 24 h and observed changes at SOX18 protein level only after 3 h treatment ( Figure 2C) . As presented by histogram, significant increase in SOX18 protein level of 1.7-fold has been detected following this treatment ( Figure 2C ). This finding is in concordance with data showing that approximately 45% of genes induced by VEGF are significantly up-regulated within the first 2-6 hours [27] . Furthermore, it has been shown that after stimulation of HUVEC with VEGF, SOX18 mRNA level raises within first two hours and declines thereafter [28] . Importantly, literature data indicate that, in vivo, the onset of murine Sox18 expression occurs after that of Vegf, around the same time as that of its receptor Flk1 (VEGF-R2) and before that of its second receptor, Flt1 (VEGF-R1) in mouse embryos and adult wound [10, 11, 29] . Thus, Sox18 expression is placed downstream of Vegf indicating that this gene could be a target of VEGF growth factor.
While the increase in the SOX18 mRNA by treatment with VEGF was demonstrated earlier [28] , here, we have presented for the first time the effect of VEGF on SOX18 protein level in human endothelial setting. This observation is of functional relevance, since both factors are marked as mediators of angiogenesis, inducing proliferation, sprouting and tube formation of endothelial cells [12, 14] .
Among other transcription factors induced by VEGF, it has been shown that EGR1 has a peak of expression after 30 minutes of treatment and is decreased thereafter [27] . Also, VEGF treatment stimulated the accumulation of EGR1 in the nucleus within 60 minutes [30] . The functional link between VEGF and EGR1 is particularly interesting since we have recently shown that SOX18 promoter activity is positively regulated by EGR1 [21] . Thus, it would be interesting to investigate whether EGR1 mediates the SOX18 expression elicited by VEGF, thereby giving a novel insight into possible functional relation between EGR1 and SOX18 during angiogenesis.
The effect of extracellular matrix proteins on SOX18 protein level in HUVEC
Endothelial cell adhesion and migration are important events during development, wound healing and angiogenesis [31] . The capacity of endothelial cells to migrate depends on the interaction between ECM proteins and cell surface integrins, which subsequently initiate intracellular signaling pathways responsible for endothelial cell spreading and migration [32] . We have therefore tested whether seeding of HUVEC in dishes pre-coated with ECM proteins could affect SOX18 expression compared to non-adherent HUVEC. For that purpose we have used collagen I and fibronectin ( Table 1) , two ECM proteins binding to integrin α 2 β 1 and α 5 β 1 /α V β 3 , respectively. Integrins α 2 β 1 and α V β 3 mediate in vitro endothelial cell attachment, spreading, and migration [33] , and are transiently localized on endothelial cells at the tips of capillary sprouts during wound repair in vivo [34] . Our results showed that none of the tested ECM proteins had effect on SOX18 protein level ( Figure 3A) , suggesting that ligation and activation of α 2 β 1 , α 5 β 1 and α V β 3 integrins does not lead to alteration of SOX18 expression in HUVEC.
The effect of TNF on SOX18 protein level in HUVEC
Tumor necrosis factor, a potent cytokine predominantly produced in macrophages, is able to induce cell death, inflammation, and to inhibit tumorigenesis and viral replication [35, 36] . Also, it has been shown that TNF stimulates angiogenesis in vivo [37] and formation of endothelial cell tubes in vitro [38] . We analyzed whether treatments of HUVEC with this cytokine for 1 h, 3 h and 5 h could affect SOX18 protein level. As presented in Figure 3B , only treatment for 3 h caused change in SOX18 protein level, while 1 h and 5 h treatments had no effect. As presented by histogram, significant increase in SOX18 protein level of 1.6-fold has been detected following 3 h treatment ( Figure 3B ). TNF-induced survival involves the activation of the transcription factor NF-κB [39] . We have performed in silico analysis and detected several putative NF-κB binding sites within the promoter of human SOX18 gene (data not shown) that could be of functional relevance for its induction by TNF. Further, it has been shown earlier that TNF has the ability to inhibit Sp1 and Sp3 binding to their consensus sites [40] . Since we have shown previously that transcription factor Sp3 acts as a repressor of SOX18 promoter activity [20] , we hypothesize that TNF induced SOX18 expression is, at least in part, associated with inhibited binding of Sp3. In addition, the expression of transcription factor EGR1, shown to be able to up-regulate SOX18 promoter activity [21] , is also stimulated by TNF [41] . 
The effect of NSAID on SOX18 protein level in HUVEC
NSAID inhibit the two isoforms of cyclooxygenase, COX-1 and COX-2, the rate-limiting enzymes on the prostanglandins biosynthetic pathway. Prostanglandins are potent pro-inflammatory molecules also able to stimulate angiogenesis in vivo and in vitro [42] [43] [44] . Thus, NSAID, among other effects, also act as antiangiogenic drugs. In this study we have used ibuprofen, as a nonspecific COX-1/2 inhibitor, and NS398, as a specific COX-2 inhibitor, to test the effect of COX inhibition on SOX18 protein expression in HUVEC. The obtained results demonstrate that selected NSAID are capable of down regulating the level of SOX18 protein in endothelial cells. In particular, after treatment of HUVEC with ibuprofen and NS398 for three hours, SOX18 protein level was decreased to approximately 50% and 25%, respectively, in comparison to control HUVEC ( Figure 4) . Regardless of the fact that NSAID act as pleiotropic agents, the demonstration that they can reduce SOX18 expression in endothelial cells, opens the possibility for pharmacological modulation of this gene expression. More importantly, we believe that finding targets of COX inhibitors that mediate some of their anti-angiogenic effects will help in selecting molecules, such as SOX18, that would become targets for other, more selective antiangiogenic agents. However, the mechanisms by which NSAID inhibit angiogenesis are likely to be multifactorial, including inhibition of mitogen-activated protein (Erk2) kinase; suppression of cell cycle proteins; inhibition of EGR1 gene activation; interference with hypoxia inducible factor 1 and VEGF gene activation; increased production of endogenous angiogenesis inhibitor; inhibition of endothelial cell proliferation, migration and spreading; and induction of endothelial apoptosis [45, 46] . Since it has been shown that NSAID inhibit the activation of egr-1 gene in microvascular endothelial cells [47] , we hypothesize that this inhibition may be functionally relevant for the down regulation of SOX18 expression.
In summary, in order to study the involvement of human SOX18 gene in signaling events that promote angiogenesis, we have demonstrated that the angiogenic factor VEGF and the pro-inflammatory cytokine TNF increase SOX18 protein level, while pan-COX-1/2 and COX-2-specific inhibitors (i.e. ibuprofen and NS398, respectively) decrease SOX18 protein level in endothelial cells. These data represent a relevant contribution to the understanding of the involvement of SOX18 in the angiogenic processes. However, this manuscript represents our initial effort in understanding the extracellular cues and intracellular signaling pathways involved in the regulation of SOX18 expression. It will serve as a basis for the future, more comprehensive work that would lead to delineation of the exact role of SOX18 in signaling events important for the angiogenic switch of endothelial cells.
Transcription factors are modulated by signaling events elicited by extracellular factors and cell surface receptors and in turn, they regulate the expression of the effector molecules in signaling cascades. In this perspective, it has been proposed that targeting particular transcription factor can affect biological process more profoundly than targeting individual upstream factor, receptor, signaling molecule or downstream effector [18] . In recent studies, Sox18 gene, expressed during initial steps of tumor vascularization, has been recognized as a potential target for antiangiogenic therapy [12] . Since tumor growth is dependent on a blood supply, anti-angiogenic therapy of cancer represents a potentially highly effective strategy for restraining tumors [48] . Thus, clarifying the complex mechanisms involved in the regulation of human SOX18 gene expression will help in better understanding of important physiological and patho-physiological processes in which this transcription factor participates.
